EUCTR2014-002341-22-AT进行中（未招募）不适用
Evaluation of the Effect of Glucagon Solutions on the Glucose Concentration at the Subcutaneous Administration Site in Type 1 Diabetic Patients.
Medizinische Universität Graz; Universitätsklinik für InnereMedizin; Abteilung für Endokrinologie und Stoffwechsel0 个研究点开始时间: 2014年6月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 18 to 64 years of age, both inclusive
- •- Type 1 diabetes treated with CSII or MDI
- •- HbA1C < 10%
- •- BMI between 20 and 30 kg/m2
- •- Signed informed consent before any study-related activities
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •- Severe acute diseases
- •- Clinically overt diabetic complications
- •- Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
- •- Taking of any vasoactive substances or anticoagulation medication
- •- Diseases of the skin which could interfere with application of catheters as judged by the investigator
- •- Uncontrolled hypertension
- •- Use of a medication that significantly impacts glucose metabolism (e.g. oral or topical steroids) except in the case of a stable state with a minimum duration of at least three months preceding the study as well as under the condition that the state remain stable for the duration of the study
- •- No superficial veins for catheter insertion as judged by the investigator
- •- Pregnancy, breastfeeding, intention of becoming pregnant or not using adequate contraception.
- •- Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject
- •- Concurrent participation in another study
研究者
相似试验
招募中
不适用
Study of glucagon response and its association with glycemic control and variability after administration of ipragliflozin as an adjunctive to insulin treatment in patients with type 1 diabetes (Suglat-AID): a single-arm, multicenter, open-label,prospective exploratory trialtype 1 diabetesJPRN-UMIN000039635agasaki University Hospital24
已完成
不适用
Effect of the glucagon suppression ability in the sulfonylurea agents and other oral hypoglycemic agents.Type 2 diabetesJPRN-UMIN000007378Divison of Diabetes and Metabolism,Itabashi Hospital, Nihon University School of Medicine200
已完成
不适用
Effect of glucagon-like-peptide-1 (GLP-1) on left ventricular function during percutaneous coronary intervention (PCI)ISRCTN77442023Papworth Hospital NHS Foundation Trust (UK)40
招募中
不适用
Glucagaon-like peptide (GLP-1) and Adipose Tissue Inflammation in Obesity StudyObesityACTRN12614000799651Associate Professor Patrick Manning12
进行中（未招募）
不适用
Investigation of the duration of the effect of the hormone glucagon on the glucose production of the liver in patients with diabetesDiabetes mellitus type 1MedDRA version: 17.1Level: LLTClassification code 10012608Term: Diabetes mellitus insulin-dependentSystem Organ Class: 100000004861EUCTR2015-000322-11-ATMedizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel